Back HIV/AIDS HIV/AIDS Topics HIV-Related Conditions

Coverage of 21st International AIDS Conference (AIDS 2016)

HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.

Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.

Full listing by topic

AIDS 2016 website

7/28/16

alt

Mild Neurological Impairment Is Common During Early HIV Infection

People with HIV infection often have neurological signs and symptoms very soon after becoming infected -- even before they develop antibodies that show up on a test -- but these are typically mild to moderate and resolve after starting effective antiretroviral therapy (ART), according to a study published in the June 10 advance online edition of Neurology. These findings provide further evidence for starting treatment as soon as possible after HIV diagnosis.

alt

Read more:

CROI 2016: Early Antiretroviral Therapy Has No Impact on Cardiovascular Disease Marker

Starting treatment at a CD4 cell count above 500 cells/mm3 does not lead to improvement in an important early warning sign of cardiovascular disease, and investigators are still unsure whether people who start treatment at high CD4 counts will have the same increased risk of cardiovascular disease as that reported in people with HIV over the past 15 years, according to findings presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston last week.

alt

Read more:

CROI 2016: Antidepressant Improves HIV-Related Cognitive Impairment

The SSRI antidepressant paroxetine (Paxil) was associated with a modest improvement in cognitive function and reduced central nervous system inflammation among people with HIV-related neurocognitive disorder, but the antifungal drug fluconazole showed no apparent benefit even though it reduced oxidative stress, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last month in Boston.

alt

Read more:

CROI 2016: Study Does Not Support Routine HPV Vaccination to Prevent Anal Cancer in People with HIV

The quadrivalent HPV vaccine Gardasil does not protect older adults with HIV against persistent anal infection with human papillomavirus or the development of high-grade anal lesions (HSIL), but the ACTG A5298 study showed some evidence that it may protect against persistent oral HPV infection, Timothy Wilkin of Weill Cornell Medical College reported at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston.

alt

Read more:

CROI 2016: Women and African Americans with HIV Have a Higher Risk of Stroke

The risk of stroke among people living with HIV is highest among people with unsuppressed viral load, and among women and African Americans, according to findings presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

Read more:

CROI 2016: Early Antiretroviral Therapy Reduces the Risk of Infection-Related Cancers

People who started antiretroviral therapy at a CD4 cell count above 500 had a significantly lower risk of developing a cancer with an infectious cause when compared to people who started treatment at a CD4 count of 350 or below, an analysis of the START study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston has shown.

alt

Read more:

CROI 2016: HIV-Related Factors Increase Risk of Stroke

HIV-related risk factors seem to increase the risk of stroke -- the sudden death of brain cells due to a rupture or obstruction of blood vessels in the brain -- according to ongoing research in a growing number of large epidemiological cohort studies. Recent data from 5 of these were presented during the first-ever poster discussion session on stroke at the Conference on Retroviruses and Opportunistic Infections (CROI), which took place last month in Boston.

alt

Read more:

Coverage of the 2016 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2016 Conference on Retroviruses and Opportunistic infections (CROI 2016), February 22-25, 2016, in Boston.

Conference highlights include PrEP and other HIV prevention innovations, new HIV treatment strategies, HIV cure research, the cascade of care, HIV-related conditions, and optimizing therapy for hepatitis C.

HIVandHepatitis.com coverage by topic

CROI website

2/26/16

alt